Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Relapsed and refractory acute lymphoblastic leukaemia in children, drawn from the whole corpus: 11 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
CD19-negative relapse and lineage switch after CD19-directed therapy.
Nothing recorded yet.
Background: Minimal / molecular residual disease (MRD). Also on OnCo: Treatment journeys · Survivorship planner.
Which children need transplant after a CAR T-cell remission.
Relapsed T-ALL has no approved immunotherapy, and CAR T-cell access is limited to a handful of countries.
Nothing recorded yet.
Background: Minimal / molecular residual disease (MRD). Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
CR+CRh 22.
ORR 77%, CR 55%; grade ≥3 CRS 2.
A milestone in how this cancer is treated.
Blinatumomab consolidation gave two-year disease-free survival of 54.
A milestone in how this cancer is treated.